Peptides DB
Research-centric peptide and protocol reference hub
Study 6 of 7GHRP-2 (Pralmorelin) literatureeuropepmc · Observational · Preclinical2022

Systemic infusion of exogenous ghrelin in male broiler chickens (Gallus gallus domesticus). The effect of pulse frequency, doses, and ghrelin forms on feed intake, average daily gain, corticosterone, and growth hormone concentrations.

AG and DAG have different effects on feed intake and growth in broiler chickens, with AG decreasing these parameters and DAG increasing them.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the ghrp-2 (pralmorelin) corpus
0
Preclinical
7
Observational · this one
0
Open-label
0
Randomised
0
Reviews

Summary and findings

This study investigated the effects of exogenous ghrelin infusion on feed intake (FI) and average daily gain (ADG) in male broiler chickens, utilizing doses of 0, 1, or 4 nM. The treatments were administered via jugular cannula over 11 days. Results indicated differential effects of acylated-ghrelin (AG) and desacylated-ghrelin (DAG) on these parameters.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Linear decrease in FI with AG infusion, P=0.002.Preclinical2022

Abstract

The authors’ words, as europepmc supplied them

There is limited information on the effect of exogenous ghrelin infusion on feed intake (FI) in chickens. Therefore, male broilers were used in 3 factorial experiments to determine the relationships between doses (0, 1, or 4 nM; Dose), frequency (once every two h; 2 h), once every 4th h (4 h) or continuous infusion, and ghrelin forms including acylated-ghrelin (AG) and desacylated-ghrelin (DAG) on FI, ADG, and concentrations of corticosterone and Growth Hormone (GH). Treatments were delivered via a jugular cannula, using programmable pumps for 11 consecutive days. FI and ADG were recorded, and plasma was collected. Data were analyzed using a factorial design. In Experiment 1 the effect of AG pulse frequency and doses were evaluated. There was a linear decrease in FI (P = 0.002) and a linear increase in corticosterone (P = 0.033) and GH (P = 0.011) concentrations when AG was infused. However, ADG decreased with doses (P = 0.011) only when AG was given at 2 h. In Experiment 2 the effect of ghrelin forms and doses given at 2 h was evaluated. There was a linear decrease in FI when AG was infused and a linear increase in FI when DAG was infused (P < 0.05). Birds infused with DAG gained more weight than those infused with AG. There was a linear increase in corticosterone and GH concentrations only when AG was infused (P < 0.01). In Experiment 3 the effect of continuous infusion of 2 doses (0 and 1 nM) of AG and DAG were evaluated. There was a linear decrease in FI and ADG when AG (P < 0.001) was infused and a linear increase in FI and ADG when DAG was infused (P < 0.05). There was an increase in corticosterone concentrations only when AG was infused (P = 0.022). However, GH concentrations were not affected by treatments. We concluded that AG and DAG pulse frequency and doses had a differential effect on FI, ADG, corticosterone, and GH concentrations in broiler chickens.

Background

The paper investigates the role of ghrelin, a hormone known to influence appetite and growth, in male broiler chickens. Previous studies have indicated that ghrelin can affect feed intake and growth metrics in various species, but the specific effects in poultry remain less understood. This research aims to clarify how different forms and dosages of ghrelin influence these parameters in chickens.

Methods

The study design involves systemic infusion of ghrelin in male broiler chickens, with varying pulse frequencies and doses. The exact sample size (n) is not reported in the abstract, nor are the specific dosages or duration of treatment. Primary outcome measures include feed intake, average daily gain, corticosterone, and growth hormone concentrations.

Results

Not reported in abstract.

Interpretation

Without specific numeric findings, it is difficult to compare the results to prior literature or assess the clinical significance of the findings. The lack of reported data limits the ability to draw conclusions about the effectiveness of ghrelin in this context. Potential confounds include the use of animal models, which may not directly translate to human applications.

Key findings

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Elsewhere in the GHRP-2 (Pralmorelin) corpus

BAssociation between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.europepmc · 2022 · n=50 · Overweight (odds ratio, 3.86; 95% confidence interval, 1.02-14.66).HumanBEffect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels.europepmc · 2023 · n=30 · Peak GH significantly and negatively predicted hs-CRP levels (β = -0.345; 95% CI, -0.533 to -0.158).HumanBPembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report.europepmc · 2024 · n=1 · Not reported in abstract.HumanBCombined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study.europepmc · 2025 · Pituitary irAEs incidence: 16/74 (21.6%) vs. 25/748 (3.3%), P<0.001HumanBSevere hyponatremia in a mild COVID-19 patient: diagnostic challenges of SIADH and adrenal insufficiency.europepmc · 2025 · Not reported in abstract.HumanBAcute Sheehan Syndrome With Distinctive Arginine Vasopressin Secretion and Magnetic Resonance Imaging Findings.europepmc · 2025 · Not reported in abstract.Human